
In this video soundbite from the EAACI 2025 symposium, Dr. Zuzana Diamant explains pathophysiological mechanisms underlying asthma and CRSwNP, and how type 2 inflammatory cytokines drive airway remodelling in patients with severe asthma. Additionally, patients with co-existing asthma and CRSwNP have a higher type 2 inflammatory burden than patients with asthma alone.
Listen to the latest updates in type 2 inflammatory science and associated skin diseases, brought to you by leading dermatology experts in the field. ADVENT On Air podcasts feature scientific conversations that explore new research into the pathophysiology, clinical features, and disease burden for a range of dermatological diseases linked to type 2 inflammation, including atopic dermatitis (AD) and prurigo nodularis (PN). Hear new insights revealed through expert-led conversations below or in your preferred podcast app.


Professor Klaus Rabe presents the latest clinical data on current and emerging biologic therapies targeting IL-33 in COPD.

From the April 2025 ADVENT Forum in Lisbon, Portugal, this event page serves to spotlight curated soundbites from dermatology and immunology experts that connect the evolving science of type 2 inflammation to clinical application.

Learn about pediatric EoE disease burden and why early identification is key for pediatric patients with EoE
Join ADVENT at the Digestive Disease Week 2024 Congress and visit the Sanofi and Regeneron Medical Booth # 1707.
In this hypothetical EoE patient case, learn about the different disease domains that are important in seeing the complete patient picture in EoE.

Prof. Peter Hellings describes how type 2 inflammation drives CRSwNP.

Professor Alberto Papi presents the latest clinical data on current and emerging biologics for COPD with type 2 inflammation.
Drs Gutiérrez Junquera and Tzivinikos discuss the importance of early identification and management of pediatric EoE to improve long-term outcomes.
In recognition of World Atopic Eczema Day 2024, ADVENT is providing medical education resources to increase the awareness of atopic dermatitis (AD).

This symposium illustrated the ways type 2inflammation contributes to atopic dermatitis (AD) disease pathogenesis within and beyond the skin, discussed the importance of early intervention in children with AD, and explored the potential for disease modification. The program concluded with a review of the latest clinical and real-world data on advanced systemic treatments for children with AD.